Obtained her PhD degree in the University of Paris VII in 1993, and trained as a post-doc in Prof. John Dick’s group in Toronto. In 1998, she became Group Leader at the Coriell Institute for Medical Research and Assistant Professor, University of Medicine and Dentistry of New Jersey. In 2001, she joined the London Research Institute. Since 2002, she is also Professor, University College of London and Senior Lecturer at the Institute of Child Health.
Graduated in Medicine in 1988 at the University of Padua. Pediatrician in 1992. I have been actively involved in pediatric hematology and oncology, especially in chemotherapy for leukemia and lymphoma, supportive care, and early and late effects of treatment, and hematopoietic stem cell transplantation (HSCT).
Appointed in 2009 Director of the Pediatric Hematology and Oncology Unit at the Department of Pediatrics in Verona. Member of the scientific committees of several working groups including Pediatrics (for MASCC), Supportive Care (for SIOP), Aplastic Anemia, Infection (for EBMT), hematopoietic stem cell transplant, Infection, Supportive care (for AIEOP). Appointed in 2005 and 2015 Chairman of the Supportive Care Group and Infection of AIEOP (Italian Association of Pediatric Hematology Oncology), respectively. Appointed in 2010, Chairman of Infectious Diseases Working Party of European Society for Blood and Marrow Transplantation.
Author of more than 200 publications in peer-reviewed journals. Medical advisor of the charities Paul O’Gorman Lifeline (UK) and Lifeline Italia, liaising with and advising pediatric hematology and oncology centers in Russia, Ukraine, Georgia and Kyrgyzstan.
Senior Lecturer in Biological Sciences at the University of Huddersfield, since 2015. Previously Junior Research Fellow, College Lecturer In Biochemistry and various postdocs at the University of Oxford (2013-15). Working on DNA replication, genome integrity and transcription factors in human cancers (and also in prokaryotes). Additional interests in phylogenomics and novel protein expression systems.
Principal Investigator of the Transfusion Research Center, Belgian Red Cross Flanders, Belgium. Winner of two PM Mannucci awards of the International Society of Thrombosis and Haemostasis and one Scott Memorial prize of the Biomedical Excellence for Safter Transfusion Collaborative.
Professor of Systems Biology and Genomics at the Harry Perkins Institute of Medical Research at the University of Western Australia, Perth. Studies transcriptional regulatory networks, cell-to-cell communication networks. Was scientific coordinator of the FANTOM5 project while based at RIKEN. Uses next generation sequencing protocols RNA-seq, Cap Analysis of Gene Expression, ChIP-seq etc and bioinformatic approaches to study transcriptional regulation.
Roi Gazit, PhD. is Principal Investigator of Hematopoietic Stem Cell (HSC) transcriptome laboratory at the Ben-Gurion University of the Negev. He is a member of the National Institute for Biotechnology in the Negev (NIBN), and the Center for Regenerative Medicine and Stem Cells at BGU. Roi earned a B.Sc. and M.Sc. in life science and developmental biology from the Hebrew University of Jerusalem. He obtained PhD in immunology, under supervision of Ofer Mandelboim, studying NK-cell in vivo, including the generation of the first NK specific mouse model and elucidation of novel NK-cell abnormalities in human patients. He conducted postdoctoral studies at the Harvard Medical School, at Derrick J. Rossi laboratory, focusing on the identification and utilization of HSCs’ genes, including reprogramming of committed blood cells into HSCs using defined transcription-factors and generation of a novel HSC-reporter mouse. His laboratory at the Ben-Gurion University is studying HSCs’ transcriptome along normal development, during immune-challenges, and the direct reprogramming of adult blood cells into HSCs.
Professor of Cellular Immunology (and Head of College of Medical and Dental Sciences Graduate School), University of Birmingham. Raine Visiting Professor, University of Western Australia. CSO & co-Founder, Celentyx Ltd.
Associate Professor of cell biology and Developmental biology in Central University of Rajasthan, India. Received PhD in Human Biology from the Institute for Prevention of Cardiovascular Diseases, Ludwig Maximilian University, Munich, Germany. Awarded “summa cum laude” for Ph.D. work.
Assistant Professor of Pediatrics at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College of Cornell University.
Professor of Molecular and Cellular Glycobiology, Department of Biological Science, College of Science, Sungkyunkwan University, Korea,
Co-positional Professor of Department of Medical Device Management and Research,
Samsung Advanced Institute of Health Science and Technology (SAIHST), Former Chairman, Department of Biochemistry and Molecular Biology, COM, DGU. Former Senior Researcher of KRIBB. University of Tokyo MS, PhD. 324 peer reviewed publications. Intl Advisory Bord and Chairs, Intl Symposium on Glycosyltransferases GlycoT2008 and GlycoT2012, Chair of Molecular Eng-2013 TX, USA. Editor, Journal of Glycobiology; eCAM, Current Pharmaceutical Biotechnology and others.
Dr. Can Küçük currently works at Dokuz Eylul University İzmir International Biomedicine and Genome Institute (iBG-izmir) in Turkey as an Assistant Professor and independent PI with his own research group. He has authored research articles in high profile journals on molecular pathobiology or diagnostics of NK and/or T cell malignancies.
Dr. Küçük graduated from the Department of Molecular Biology and Genetics at Middle East Technical University (METU) in 2005. He got his Ph.D degree in Cancer Biology and Oncology from Eppley Institute for Research in Cancer and Allied Diseases at University of Nebraska Medical Center (UNMC) in 2012. He worked as a post-doc in the Department of Pathology at UNMC and then at City of Hope Medical Center.
His group investigates the etiology of lymphoid malignancies using personalized medicine approach. In particular, whole-exome sequencing or whole transcriptome sequencing are applied on tumor samples to identify aberrant genes or pathways leading to development of these neoplasms. His group aims to:
1) identify novel recurrent aberrations that can be targeted by rational drugs.
2) develop companion diagnostics methodologies for personalized medicine
3) identify novel biomarkers of diagnosis, prognosis or disease management.
The other areas of research interest in Dr. Küçük lab can be described as follows:
a) Rare diseases
My research group is working to identify genetic mutations that contribute to the development of leukaemia, and studying how these mutations influence a patient’s response to therapy. The cancer landscape is both complex and dynamic and we're using genomic approaches to study how cancer cells evolve in response to treatment.